Report Details:
15 Companies Covered
90 Pages
Dry Eye Syndrome Market is expected to grow at a considerable 5.33% CAGR from 2025 to 2035 | MRFR
Market Research Future (MRFR) has published a cooked research report on the “Global Dry Eye Syndrome Market” that contains information from 2019 to 2035. The Dry Eye Syndrome Market is estimated to register a CAGR of 5.33% during the forecast period of 2025 to 2035.
MRFR recognizes the following companies as the key players in the Global Dry Eye Syndrome Market — Allergan, Novartis, Regeneron Pharmaceuticals, Zylo Therapeutics, Eyevage, Clearside Biomedical, Ocuphire Pharma, Johnson & Johnson, Bausch Health, Otsuka Pharmaceutical, Santen Pharmaceutical, Horizon Therapeutics, Shire, Kalia Health, and AbbVie.
Market Highlights
The Global Dry Eye Syndrome Market is accounted for to register a CAGR of 5.33% during the forecast period and is estimated to reach USD 9.15 Billion by 2035.
The market growth is driven by the increasing prevalence of dry eye conditions, rising screen time, and the aging population, which collectively contribute to the growing demand for effective treatment options. Moreover, environmental factors and increasing awareness about eye health are boosting early diagnosis and treatment adoption across various regions.
Technological advancements and innovations in drug formulations, such as preservative-free artificial tears and advanced anti-inflammatory drugs, are improving treatment efficacy and patient compliance. The expansion of telehealth platforms is further enhancing access to eye care and supporting remote diagnosis and treatment of dry eye conditions.
Companies such as Allergan and Novartis are actively investing in R&D and expanding their therapeutic portfolios. For instance, in 2023, Bausch Health introduced a new dry eye treatment targeting severe symptoms, while Ocuphire Pharma made progress with clinical trials for innovative therapies. Strategic mergers, such as Johnson & Johnson’s 2023 acquisition of a leading dry eye treatment firm, have strengthened market positions and accelerated innovation.
Segment Analysis
The Global Dry Eye Syndrome Market has been segmented based on Product Type, Cause of Dry Eye Syndrome, Distribution Channel, and End User.
- By Product Type, the market includes Artificial Tears, Anti-Inflammatory Drugs, Punctal Plugs, and Surgical Devices. The Artificial Tears segment dominated in 2024 due to widespread usage and affordability.
- By Cause of Dry Eye Syndrome, Aging held the largest market share, followed by Environmental Factors and Medication-Induced causes.
- By Distribution Channel, Retail Pharmacy and Online Pharmacy segments are witnessing strong growth due to increased accessibility and convenience.
- By End User, Hospitals and Ophthalmology Clinics accounted for the majority of the market share in 2024.
Region Analysis
By Region, the Dry Eye Syndrome Market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
- North America held the largest market share in 2024, valued at USD 2.1 Billion, and is projected to reach USD 3.5 Billion by 2035, driven by growing awareness, advanced healthcare infrastructure, and the presence of leading pharmaceutical companies.
- Europe followed, supported by increased diagnosis and strong investment in eye care.
- Asia-Pacific is expected to be the fastest-growing region, expanding from USD 0.85 Billion in 2024 to USD 1.8 Billion by 2035, owing to rapid urbanization, increased digital screen exposure, and growing healthcare access.
- South America and Middle East & Africa are emerging markets with increasing awareness and improving healthcare systems.
Key Findings of the Study
- The Global Dry Eye Syndrome Market is expected to reach USD 9.15 Billion by 2035, at a CAGR of 5.33% during the forecast period.
- North America accounted for the largest market share, while Asia-Pacific is projected to be the fastest-growing region.
- Based on Product Type, the Artificial Tears segment dominated the market in 2024.
- Based on End User, Hospitals and Ophthalmology Clinics held the largest shares in 2024.
- Allergan, Novartis, Regeneron Pharmaceuticals, Johnson & Johnson, and Bausch Health are identified as key market players.